Allogene Therapeutics (ALLO) FCF Margin (2021 - 2024)
Allogene Therapeutics' (ALLO) quarterly FCF Margin came in at 254122.73% in Q1 2024, down 2854273.0% year-on-year from N/an in Q2 2023, and up 0.97% quarter-over-quarter from 256609.52% in Q4 2023.
Allogene Therapeutics (ALLO) FCF Margin (2021 - 2024) Analysis & Trends
Allogene Therapeutics has disclosed FCF Margin across 4 years of filings, most recently posting 254122.73% for Q1 2024.
- FCF Margin for Q1 2024 came in at 254122.73%, down 2854273.0% year-over-year; the trailing twelve-month figure through Dec 2024 was 913609.09% (down 66176804.0% YoY), and the FY2024 annual result was 913609.09%, down 66176804.0% from the prior year.
- FCF Margin came in at 254122.73% for Q1 2024 at Allogene Therapeutics, up from 256609.52% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 34.96% in Q4 2021 to a low of 282477.27% in Q2 2023.
- The 4-year median for FCF Margin is 179843.59% (2022), against an average of 165072.31%.
- Peak annual rise in FCF Margin reached 4556662 bps in 2022, while the deepest fall reached 22794580 bps in 2022.
- Allogene Therapeutics' FCF Margin stood at 34.96% in 2021, then plunged by 651935 bps to 227980.77% in 2022, then declined by 13 bps to 256609.52% in 2023, then grew by 1 bps to 254122.73% in 2024.
- The last three FCF Margin figures came in at 254122.73% (Q1 2024), 256609.52% (Q4 2023), and 252463.64% (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Allogene Therapeutics | 482.98 Mn | 482.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -254,122.73% |
| Dec 31, 2023 | -256,609.52% |
| Sep 30, 2023 | -252,463.64% |
| Jun 30, 2023 | -282,477.27% |
| Mar 31, 2023 | -225,580.00% |
| Dec 31, 2022 | -227,980.77% |
| Sep 30, 2022 | -177,325.93% |
| Jun 30, 2022 | -68,601.56% |
| Mar 31, 2022 | -179,843.59% |
| Dec 31, 2021 | -34.96% |
| Sep 30, 2021 | -106,581.63% |
| Jun 30, 2021 | -114,168.18% |
| Mar 31, 2021 | -150.29% |